Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.

Nuvaira, a US-based developer of treatments for obstructive lung diseases, closed a $79m series E round on Monday led by venture capital firm US Venture Partners.
The round also featured venture capital firms Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, Advanced Technology Ventures (ATV), Split Rock Partners and Windham Venture Partners as well as philanthropic outfit Richard King Mellon Foundation.
Investment firms Morgenthaler Ventures and company builder Versant Ventures also took part, as did Vertex Venture, the venture…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in